Valuation: AbbVie Inc.

Capitalization 412B 348B 318B 304B 562B 37,305B 583B 3,707B 1,468B 17,994B 1,544B 1,512B 63,218B P/E ratio 2025
96.8x
P/E ratio 2026 * 24.6x
Enterprise value 468B 396B 361B 346B 639B 42,420B 663B 4,215B 1,669B 20,461B 1,755B 1,719B 71,886B EV / Sales 2025
6.6x
EV / Sales 2026 * 6.87x
Free-Float
96.39%
Yield 2025 *
2.81%
Yield 2026 * 2.98%
1 day+0.59%
1 week+4.68%
Current month+4.42%
1 month+8.64%
3 months-0.49%
6 months+12.66%
Current year+1.91%
1 week 220.91
Extreme 220.91
235.25
1 month 204.27
Extreme 204.27
235.25
Current year 204.27
Extreme 204.27
237.04
1 year 164.39
Extreme 164.39
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 102.05
Extreme 102.05
244.81
10 years 53.74
Extreme 53.74
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/01/2003
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
+0.59%+4.68%+20.73%+53.90% 412B
-0.38%+1.08%+22.72%+215.48% 926B
-0.05%+2.09%+55.83%+51.71% 586B
+0.14%+3.48%+25.19%+31.83% 382B
+0.39%+5.51%+32.63%+35.48% 326B
+0.42%+4.73%+34.05%+61.43% 317B
+0.13%+3.77%+46.45%+11.00% 302B
+0.23%+1.19%-47.13%-36.90% 218B
+1.13%+2.39%+28.23%+55.22% 201B
+0.19%+5.46%+49.18%+83.19% 193B
Average +0.28%+3.39%+26.79%+56.24% 386.18B
Weighted average by Cap. +0.14%+3.07%+29.06%+82.23%

Financials

2025 2026 *
Net sales 60.96B 51.54B 47.07B 45.06B 83.25B 5,525B 86.3B 549B 217B 2,665B 229B 224B 9,364B 67.08B 56.71B 51.79B 49.58B 91.6B 6,080B 94.96B 604B 239B 2,933B 252B 246B 10,304B
Net income 7.42B 6.28B 5.73B 5.49B 10.14B 673B 10.51B 66.88B 26.48B 325B 27.85B 27.27B 1,141B 17.37B 14.69B 13.41B 12.84B 23.72B 1,575B 24.59B 156B 61.96B 759B 65.15B 63.8B 2,668B
Net Debt 56.43B 47.71B 43.57B 41.71B 77.06B 5,115B 79.89B 508B 201B 2,467B 212B 207B 8,668B 49.35B 41.72B 38.1B 36.48B 67.39B 4,473B 69.86B 444B 176B 2,158B 185B 181B 7,580B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).
Employees
55,000
Date Price Change Volume
17/02/26 232.86 $ +0.59% 7,336,770
13/02/26 231.50 $ +1.76% 8,252,480
12/02/26 227.50 $ +2.99% 8,712,013
11/02/26 220.89 $ -0.70% 8,072,636
10/02/26 222.44 $ -0.37% 6,044,475
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
232.86USD
Average target price
246.63USD
Spread / Average Target
+5.91%

Quarterly revenue - Rate of surprise